Labiotech.eu

News and Trends 8 Apr 2016

Biotech of the Week: Activartis Immuno-Oncology in Vienna

This week, we leave Milan and head once again towards the East. Vienna: Austria’s palatial and stunning capital city is our destination, and is also where our Biotech of the week, Activartis, is located. City: Vienna (Austria) Founded: 2003 Employees: 11 – 50 (as of 12/2015) Financial Data: N/A CEO: Thomas Felzmann Mission: Currently in phase II clinical […]

April 8, 2016 - 1 minutemin - By Joachim Eeckhout

News and Trends 8 Apr 2016

French Gene Technology and Bayer to ‘Unlock’ Food Crop Diversity

Meiogenix (France) has signed with Bayer Crop Science (Germany) for use of their gene-editing platform, to try and ‘Unlock’ crop genetic diversity and improve food security. Launched in 2011, this Parisian biotech was a spin-off of the Institut Curie and the French Agricultural Agency (INRA) after successfully raised funding. Now, under this non-exclusive agreement, Meiogenix […]

April 8, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Apr 2016

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer’s, to Allergan for up to €3Bn. A good way for Allergan to ‘get over’ yesterday’s failed Pfizer acquisition. Based in Cambridge, UK, Heptares Therapeutics is creating new therapies with their StaR platform, that allows it to target G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to many […]

April 7, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 7 Apr 2016

Two of the Biggest European Biotechs launch Antibody Program together

MorphoSys (Germany) and Galapagos (Belgium) have announced a new joint program to conduct a phase I trial for a first-in-class antibody, MOR106, that could be used to treat inflammatory diseases. Just after announcing that it is suing Janssen Biotech and Genmab (Denmark), Munich-based MorphoSys is still keeping things interesting – this time with a phase I trial for […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 7 Apr 2016

This Successful Phase III Cancer Drug comes from Sea Squirts

PharmaMar is closer to have another cancer drug on the market, after the success of phase III trials with Aplidin for Multiple Myeloma. Based in Madrid, PharmaMar is a Biopharma developing anti-cancer drugs, with an interesting strategy for drug discovery. It researches compounds present in marine organisms and assess if they have any biological action […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 6 Apr 2016

Interviewing the Swedish Biotech that started the first Phase II Trial in Bahrain

It’s the fist time I heard of a European Biotech company clinically co-operating with a country in the Arabic gulf… That’s why I was curious to interview Christina Herder, the CEO of the Stockholm-based Dilaforette, which launched a Phase II trial in co-operation with Bahrain and the rest of the Emirates. Dilaforette, as many Swedish […]

April 6, 2016 - 1 minutemin - By Philip Hemme

News and Trends 6 Apr 2016

This 27-year-old Woman is Shaking up the Scientific Publishing Industry

During my studies, I was always frustrated by the pay-walls standing between my assignments and the references I needed to access. Alexandra Elbakyan is trying to solve this problem. This 27-year-old woman had the skills (and guts) to create SciHub, the ‘Napster of scientific publication’. The scientific publication industry is generating $10Bn annual revenues, has margins around 30% and is controlled by […]

April 6, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 5 Apr 2016

Interviewing one of the Leading Biotech Investors in Scandinavia

The Karolinska Institute (Sweden) is worldwide famous for giving the Nobel Prize every year… It’s also home of Karolinska Development, an investment company span out from Karolinska Institute. I had the chance to meet with Viktor Drvota, its Chief Investment Officer at BIO-Europe Spring 2016 in Stockholm. We had a chance to talk about the […]

April 5, 2016 - 1 minutemin - By Philip Hemme

News and Trends 5 Apr 2016

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Samsung Bioepis (South Korea) has gotten an approval recommendation from the EMA for one of its 13 in-development biosimilars: Flixabi, a biosimilar of Janssen’s blockbuster Remicade for Inflammatory diseases. Samsung Bioepis is a joint venture between Biogen and Samsung BioLogics, a branch of the Korean giant that provides manufacturing services for development of biologicals. It started developing […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 5 Apr 2016

Israeli Cancer Startup catches Investment from 3 major Big Pharma

Metabomed is developing new highly-selective drugs that target cancer metabolism – and it has now raised €15.8M in a series A round and gotten a new CEO from Merck’s ranks. Metabomed was co-founded by MS Ventures (the VC arm of Merck KGaA) and leading researchers in the field of cancer metabolism and computational biology back in 2014. I must […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 5 Apr 2016

How can we Optimise DNA Extraction from Human Blood for more Sensitive NGS Analysis?

The increasing relevance of Next Generation Sequencing (NGS) in genetic research means there is a high demand for nucleic acid isolation from human fluids. So how can we perform efficient DNA extraction from human blood? NGS has revolutionised genetic research, by serving as a powerful processing technology, cutting time taken to run genetic analysis and also the cost. […]

April 5, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Apr 2016

Allergy Immunotherapy from Switzerland gets several Million in funding

Anergis (Switzerland) has gotten €4.5M from investors and is planning a phase IIb trial for ATIBAR, its leading candidate to treat Tree allergies. Anergis is developing ultra-fast immunotherapies for allergies, which could be an interesting alternative to current treatments, known as ‘desensitization’ or conventional Allergy Immunotherapy (AIT). This process of inducing tolerance to the allergen requires 3-5 […]

April 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Biotech of the Week: Activartis Immuno-Oncology in Vienna

French Gene Technology and Bayer to ‘Unlock’ Food Crop Diversity

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

Two of the Biggest European Biotechs launch Antibody Program together

This Successful Phase III Cancer Drug comes from Sea Squirts

Interviewing the Swedish Biotech that started the first Phase II Trial in Bahrain

This 27-year-old Woman is Shaking up the Scientific Publishing Industry

Interviewing one of the Leading Biotech Investors in Scandinavia

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Israeli Cancer Startup catches Investment from 3 major Big Pharma

How can we Optimise DNA Extraction from Human Blood for more Sensitive NGS Analysis?

Allergy Immunotherapy from Switzerland gets several Million in funding

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!